Health Canada Opens Consultation on Decentralized Clinical Trials Guidance as Global Regulatory Frameworks Converge
核心洞察
Health Canada has opened a public consultation on draft guidance for decentralized clinical trials, running from December 23, 2025, to February 21, 2026, seeking input from sponsors, investigators, healthcare providers, and patients.
The draft guidance outlines regulatory considerations for trials where some or all activities occur outside traditional clinical sites using digital health technologies and virtual methods.
A comprehensive review reveals that major regulatory authorities including FDA, EMA, and NMPA have developed converging frameworks for DCTs, focusing on risk assessment, study design, digital elements, data governance, and stakeholder communication.
Health Canada has launched a public consultation on draft guidance for decentralized clinical trials (DCTs), marking another significant step in the global regulatory evolution toward modernized clinical research frameworks. The consultation, which opened on December 23, 2025, and will close on February 21, 2026, seeks input from clinical trial sponsors, investigators, healthcare providers, industry stakeholders, and patients interested in participating in clinical trials.
The draft guidance outlines regulatory considerations and practical strategies for conducting clinical trials with decentralized elements in Canada, where some or all trial-related activities take place at locations other than traditional clinical trial centers using digital health technologies and virtual methods. These considerations align with Part C, Division 5 of the Food and Drug Regulations and are supported by the International Council for Harmonization Guideline for Good Clinical Practice (ICH E6).
Addressing Clinical Trial Accessibility and Diversity
According to Health Canada, decentralized elements can reduce travel burden for participants, make clinical trials more accessible and diverse, and connect researchers and healthcare providers in remote areas to pan-Canadian research efforts. This initiative comes as the pharmaceutical industry grapples with persistent challenges in clinical trial participation and diversity.
A 2017 global survey by the Center for Information and Study on Clinical Research Participation (CISCRP (搜索)) distributed questionnaires to approximately 120,400 people across 68 countries, achieving only a 10% response rate. Of the respondents, merely 3,848 people expressed interest in participating in clinical trials, highlighting the significant barriers to trial participation that DCTs aim to address.
The FDA has been actively advocating for diversity in clinical trial participants over the past decade, yet underrepresentation remains a persistent problem. In 2022, the FDA issued a Reform Act to improve recruitment and retention of diverse participants in clinical trials, specifically including decentralized elements, digital health technology, and innovative design in recruitment strategies.
Global Regulatory Convergence
A comprehensive analysis of regulatory frameworks across major jurisdictions reveals significant convergence in DCT approaches. The United States, Europe, and China have all developed frameworks that can be broadly categorized into five key areas: risk assessment of the new paradigm, study design, digital elements (including electronic informed consent, digital therapeutic products, telemedicine, and remote monitoring), data governance, and stakeholder communication.
The U.S. FDA has demonstrated relatively advanced regulatory action, issuing specific guidance on DCTs and launching initiatives such as the Pre-Cert Program and the Software as a Medical Device (SaMD) framework. The FDA's approach emphasizes efficiency and has included Patient-Focused Drug Development concepts since 2012, followed by the 21st Century Cures Act's promotion of real-world studies.
In Europe, the EMA relies heavily on coordination among national competent authorities, often resulting in fragmented implementation across member states. However, Europe has placed greater emphasis on empowering patients through education and training, with initiatives such as the European Patients' Academy on Therapeutic Innovation (EUPATI), launched in 2012 to enhance effective patient-researcher partnerships.
China's regulatory framework continues to evolve, with the National Medical Products Administration (NMPA) issuing its first comprehensive regulatory guidance on DCTs in 2024, primarily focusing on rare diseases (搜索). This reflects a cautious stance by Chinese regulatory authorities, favoring pilot programs within narrowly defined populations.
Financial and Operational Benefits
Research demonstrates significant financial advantages of DCTs. A study using an expected net present value (eNPV) model found that applying decentralized clinical trials to Phase II and Phase III trials could increase the return on investment (ROI) of a drug prior to Phase II by seven-fold.
This financial benefit comes at a critical time for the pharmaceutical industry. A 2019 Deloitte report showed that the average cost of launching a new drug increased from US$1.188 billion in 2010 to US$1.981 billion in 2019, while average predicted maximum sales volume decreased from US$816 million to US$376 million over the same period. Consequently, the expected internal rate of return dropped from 10.1% in 2010 to 1.8% in 2019.
Digital Health Technology Integration
DCTs facilitate the integration of various digital health technologies that can effectively reduce burden on participants and staff. These technologies have been classified into four categories: available remote solutions, those requiring additional technical development and/or validation, solutions unlikely to be fully remote, and those where remote solutions are not possible.
The implementation of digital health technologies generates more real-world data, which can be leveraged to create real-world evidence, driving innovation in new drug development. However, this technological integration also presents challenges, particularly regarding the digital divide and cybersecurity concerns.
Addressing Implementation Challenges
Despite the promise of DCTs, several challenges remain. The digital divide represents a significant barrier, particularly for vulnerable populations who may lack access to digital resources or the skills to use them effectively. As defined by Christine Bost, President of Bordeaux Metropole, the digital divide represents "a significant gap between individuals who have access to digital resources and those who do not," which could worsen existing inequalities.
Cybersecurity and data protection have become paramount concerns. In 2022, Section 524B was added to the Federal Food, Drug, and Cosmetic Act to strengthen cybersecurity for medical devices, with guidelines being applied to digital clinical trials. The European Union's General Data Protection Regulation (GDPR), effective since 2018, provides comprehensive provisions for personal information protection that sponsors must consider in DCT design.
Ethical and Infrastructure Considerations
The implementation of DCTs introduces ethical challenges across three key areas: personal safety and rights (including self-storage and monitoring of investigational products and privacy protection), scientific validity (ensuring digital endpoints and biomarkers are scientifically validated), and ethical oversight (determining which trials are suitable for decentralized models).
Infrastructure requirements remain critical for DCT success. Reliable physical and operational infrastructure, including power supply, Internet access, smartphones and applications, email systems, and cold-chain logistics for investigational products and specimens, forms the foundation for sustainable DCT development.
Future Regulatory Harmonization
While regional regulatory expectations for DCTs exhibit certain differences, their commonalities far outweigh the divergences. This convergence likely reflects broader globalization trends and sustained international dialogue over recent decades. The International Council for Harmonization (ICH) is positioned to play a proactive role in leading further harmonization efforts related to DCTs, ensuring consistency and efficiency across regions.
Canada's approach through this consultation represents part of a broader global effort to modernize clinical trial regulation. The country's Clinical Trials Remote Access Framework (CRAFT) has outlined eight key elements for DCT consideration: infrastructure and personnel development, costs and funding requirements, trial planning and conduct, regulatory guidelines and inspections, ethics review, patient privacy, trial agreements and insurance, and engagement and communication.
As the consultation period progresses, stakeholders can submit feedback via email to bpsip-bpspiconsultation@hc-sc.gc.ca or by mail to the Bureau of Policy, Science and International Programs at Health Canada. The final guidance will be developed based on public feedback, contributing to the global framework for modernized clinical research that balances innovation with patient safety and scientific rigor.